Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Antiverse Raises $9.3M, Enters Research Pact with Cystic Fibrosis Foundation | Contract Pharma
Breaking News

Antiverse Raises $9.3M, Enters Research Pact with Cystic Fibrosis Foundation

Funding to accelerate internal pipeline and advance lead antibody programs toward in vivo efficacy studies.

Antiverse

Pictured: Murat Tunaboylu, Co-Founder and CEO, Antiverse, and Ben Holland, Co-Founder and CTO, Antiverse.

Antiverse, an AI-driven techbio company developing therapeutic antibodies for historically undruggable targets, has raised a $9.3 million Series A and announced a research agreement with the Cystic Fibrosis Foundation.

The round was led by Soulmates Ventures with participation from Innovation Investment Capital, DOMiNO Ventures, and existing investors, bringing total funding to over $20 million. Proceeds will advance Antiverse’s internal pipeline toward in vivo efficacy studies and further scale its generative AI platform and in-house lab capabilities.

Under the new agreement, Antiverse will design and optimize novel antibodies targeting the extracellular region of CFTR — a notoriously difficult domain — using its AI-driven modelling platform and proprietary lab-in-the-loop workflow, before transferring candidates to the Foundation for testing in native cell models.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters